戴纳基(DYN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DYN 戴纳基

休市中 03-20 16:00:00 EDT

17.56

-0.24

-1.35%

盘后17.56

+0.000.00%

18:03 EDT

最高18.84	最低17.25	成交量506.47万
今开17.88	昨收17.80	日振幅8.93%
总市值28.98亿	流通市值26.69亿	总股本1.65亿
成交额9,001万	换手率3.33%	流通股本1.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DYN","market":"US","secType":"STK","nameCN":"戴纳基","latestPrice":17.56,"timestamp":1774036800000,"preClose":17.8,"halted":0,"volume":5064735,"hourTrading":{"tag":"盘后","latestPrice":17.56,"preClose":17.56,"latestTime":"18:03 EDT","volume":752797,"amount":13218939.4561,"timestamp":1774044222074,"change":0,"changeRate":0,"amplitude":0.01139},"delay":0,"changeRate":-0.013483146067415842,"floatShares":152000000,"shares":165027119,"eps":-3.47403,"marketStatus":"休市中","change":-0.24,"latestTime":"03-20 16:00:00 EDT","open":17.88,"high":18.84,"low":17.25,"amount":90009249.818865,"amplitude":0.089326,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.47403,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1600315200000,"exchange":"NASDAQ","adjPreClose":17.8,"preHourTrading":{"tag":"盘前","latestPrice":17.7897,"preClose":17.8,"latestTime":"08:02 EDT","volume":2638,"amount":47684.46162,"timestamp":1774008120109,"change":-0.0103,"changeRate":-0.000579,"amplitude":0.066854},"postHourTrading":{"tag":"盘后","latestPrice":17.56,"preClose":17.56,"latestTime":"18:03 EDT","volume":752797,"amount":13218939.4561,"timestamp":1774044222074,"change":0,"changeRate":0,"amplitude":0.01139},"volumeRatio":2.042009312969583,"impliedVol":0.2428,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/DYN","defaultTab":"news","newsList":[{"id":"1162385159","title":"戴纳基启动Z-Basivarsen治疗1型强直性肌营养不良症的三期Harmonia试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162385159","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162385159?lang=zh_cn&edition=full","pubTime":"2026-03-09 06:02","pubTimestamp":1773007331,"startTime":"0","endTime":"0","summary":"戴纳基公司宣布，正式启动其候选药物Z-Basivarsen针对1型强直性肌营养不良症（DM1）的三期Harmonia临床试验。这一关键性研究旨在评估该疗法在DM1患者中的安全性与有效性，标志着公司在神经肌肉疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","BK4139","DYN"],"gpt_icon":0},{"id":"1132870393","title":"戴纳基公布24个月数据：Z-rostudirsen在DMD治疗中显著改善心肺功能","url":"https://stock-news.laohu8.com/highlight/detail?id=1132870393","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132870393?lang=zh_cn&edition=full","pubTime":"2026-03-09 06:01","pubTimestamp":1773007276,"startTime":"0","endTime":"0","summary":"最新公布的24个月临床数据显示，戴纳基（Dyne Therapeutics）研发的Z-rostudirsen在治疗杜氏肌营养不良症（DMD）过程中，对患者的心肺功能产生持续性改善。这一突破性进展为DMD患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","DYN","BK4588","BK4139"],"gpt_icon":0},{"id":"1176762845","title":"戴纳基公布Z-Rostudirsen治疗杜氏肌营养不良症DELIVER试验新积极心肺结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1176762845","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176762845?lang=zh_cn&edition=full","pubTime":"2026-03-09 06:00","pubTimestamp":1773007216,"startTime":"0","endTime":"0","summary":"戴纳基公司近日宣布，其针对杜氏肌营养不良症研发的Z-Rostudirsen药物在DELIVER临床试验中取得了新的积极心肺功能数据。这项突破性进展标志着该疗法在改善患者心肺系统关键指标方面展现出显著潜力，为DMD治疗领域注入了新的希望。试验结果显示，Z-Rostudirsen在多项心肺功能评估参数上均表现出具有临床意义的改善。该公司表示将持续推进Z-Rostudirsen的研发进程，力争为DMD患者提供更有效的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","BK4585","BK4139","DYN"],"gpt_icon":0},{"id":"1117813638","title":"戴纳基Dyne-101获日本孤儿药认定，用于治疗1型强直性肌营养不良症","url":"https://stock-news.laohu8.com/highlight/detail?id=1117813638","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117813638?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:32","pubTimestamp":1768912335,"startTime":"0","endTime":"0","summary":"戴纳基治疗公司宣布，其针对1型强直性肌营养不良症的在研药物Zeleciment Basivarsen（研发代号：Dyne-101）已获得日本厚生劳动省授予的孤儿药认定。此项认定标志着该药物在日本的开发进程迈出了重要一步，为后续的临床研究、审评审批以及潜在的市场准入奠定了基础。孤儿药资格通常能为药物开发者带来诸如税收减免、研发资助以及市场独占期等一系列政策优惠与支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","BK4505","DYN"],"gpt_icon":0},{"id":"1127475435","title":"戴纳基股价在盘前上涨3.6%，因公司公布肌肉疾病治疗药物的早期至中期临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1127475435","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127475435?lang=zh_cn&edition=full","pubTime":"2025-12-08 19:50","pubTimestamp":1765194601,"startTime":"0","endTime":"0","summary":"戴纳基股价在盘前上涨3.6%，因公司公布肌肉疾病治疗药物的早期至中期临床试验数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","DYN","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"1141062647","title":"戴纳基公布Z-Rostudirsen在杜氏肌营养不良症（DMD）的一期/二期Deliver试验中取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1141062647","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141062647?lang=zh_cn&edition=full","pubTime":"2025-12-08 19:33","pubTimestamp":1765193595,"startTime":"0","endTime":"0","summary":"戴纳基公布Z-Rostudirsen在杜氏肌营养不良症（DMD）的一期/二期Deliver试验中取得积极的顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","DYN","BK4139","BK4585","BK4505"],"gpt_icon":0},{"id":"2584967027","title":"戴纳基盘中异动 下午盘大幅上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584967027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584967027?lang=zh_cn&edition=full","pubTime":"2025-11-19 02:25","pubTimestamp":1763490313,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日02时25分，戴纳基股票出现波动，股价急速上涨5.04%。截至发稿，该股报21.26美元/股，成交量118.282万股，换手率0.83%，振幅8.37%。戴纳基股票所在的生物技术行业中，整体涨幅为0.40%。FORCE 平台的治疗药物包括一个合理设计以针对疾病遗传基础的药物载体、一个连接子和一个抗原结合片段，抗原结合片段通过连接子连接到药物载体上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511190225149771b020&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511190225149771b020&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","DYN","BK4585","BK4505"],"gpt_icon":0},{"id":"2581886929","title":"戴纳基盘中异动 快速下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581886929?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:35","pubTimestamp":1762439735,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时35分，戴纳基股票出现波动，股价快速跳水5.02%。截至发稿，该股报19.85美元/股，成交量6.7481万股，换手率0.05%，振幅6.32%。机构评级方面，在所有16家参与评级的机构中，81%的券商给予买入建议，19%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体涨幅为0.10%。戴纳基公司简介：Dyne Therapeutics Inc 是一家处于临床阶段的神经肌肉疾病公司，专注于发现和推进针对遗传性神经肌肉疾病患者的变革性治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223536a6e635c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223536a6e635c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","BK4505","DYN"],"gpt_icon":0},{"id":"2574101977","title":"戴纳基盘中异动 急速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574101977","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574101977?lang=zh_cn&edition=full","pubTime":"2025-10-10 23:01","pubTimestamp":1760108483,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日23时01分，戴纳基股票出现异动，股价快速跳水5.01%。截至发稿，该股报13.95美元/股，成交量43.1644万股，换手率0.30%，振幅2.17%。机构评级方面，在所有16家参与评级的机构中，81%的券商给予买入建议，19%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体跌幅为0.63%。消息层面，截至23时01分，《摩根士丹利维持戴纳基买入评级，维持目标价48美元》资讯为影响戴纳基的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101023012394c20a66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101023012394c20a66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DYN","BK4139","BK4505","BK4585","BK4588"],"gpt_icon":0},{"id":"1147655715","title":"戴纳基公布额外一年临床数据，显示治疗肌强直性营养不良1型药物Zeleciment Basivarsen在1/2期ACHIEVE试验中展现功能性改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1147655715","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147655715?lang=zh_cn&edition=full","pubTime":"2025-10-07 06:02","pubTimestamp":1759788136,"startTime":"0","endTime":"0","summary":"戴纳基近日公布了其候选药物Zeleciment Basivarsen (Dyne-101)在治疗肌强直性营养不良1型(DM1)方面的额外一年临床数据。该数据来自1/2期ACHIEVE试验，结果显示患者出现功能性改善。\n这项临床试验为期一年的追踪数据进一步证实了Zeleciment Basivarsen在治疗这种罕见遗传性疾病方面的潜在疗效。肌强直性营养不良1型是一种影响肌肉功能的遗传性疾病，目前缺乏有效的治疗选择。\nACHIEVE试验的最新数据为该药物的进一步开发提供了重要支持，也为DM1患者群体带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4505","BK4139","DYN"],"gpt_icon":0},{"id":"1123331202","title":"戴纳基Dyne Therapeutics旗下Dyne-251获得日本孤儿药认定，用于治疗杜氏肌营养不良症","url":"https://stock-news.laohu8.com/highlight/detail?id=1123331202","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123331202?lang=zh_cn&edition=full","pubTime":"2025-09-29 20:37","pubTimestamp":1759149445,"startTime":"0","endTime":"0","summary":"戴纳基Dyne Therapeutics宣布，其药物候选产品Dyne-251已获得日本监管部门的孤儿药认定，该药物用于治疗杜氏肌营养不良症。这一认定为公司在日本市场推进该治疗方案的开发提供了重要的监管支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DYN","BK4505","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2568118216","title":"戴纳基盘中异动 急速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568118216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568118216?lang=zh_cn&edition=full","pubTime":"2025-09-20 02:48","pubTimestamp":1758307682,"startTime":"0","endTime":"0","summary":"北京时间2025年09月20日02时48分，戴纳基股票出现波动，股价大幅下跌5.03%。截至发稿，该股报13.22美元/股，成交量88.1149万股，换手率0.62%，振幅5.17%。机构评级方面，在所有17家参与评级的机构中，88%的券商给予买入建议，12%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体跌幅为0.56%。戴纳基公司简介：Dyne Therapeutics Inc 是一家处于临床阶段的神经肌肉疾病公司，专注于发现和推进针对遗传性神经肌肉疾病患者的变革性治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920024802a4378dbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920024802a4378dbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","DYN","BK4588","BK4585"],"gpt_icon":0},{"id":"2518227151","title":"戴纳基盘中异动 早盘急速下跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518227151?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:48","pubTimestamp":1741614488,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时48分，戴纳基股票出现异动，股价急速下跌5.24%。截至发稿，该股报11.75美元/股，成交量6.3116万股，换手率0.06%，振幅5.75%。机构评级方面，在所有13家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体涨幅为0.26%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214809abf302ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214809abf302ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","BK4139","BK4585","DYN"],"gpt_icon":0},{"id":"2517452626","title":"戴纳基2024财年实现净利润-3.17亿美元，同比减少34.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517452626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517452626?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363243,"startTime":"0","endTime":"0","summary":"3月8日，戴纳基公布财报，公告显示公司2024财年净利润为-3.17亿美元，同比减少34.32%；其中营业收入为0.00美元，每股基本收益为-3.37美元。从资产负债表来看，戴纳基总负债61.40百万美元，其中短期债务4.85百万美元，资产负债比为0.12，流动比率为0.16。机构评级：截至2025年3月8日，当前有13家机构对戴纳基目标价做出预测，其中目标均价为48.15美元，其中最低目标价为18.00美元，最高目标价为66.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000127abed6604&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000127abed6604&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DYN"],"gpt_icon":0},{"id":"2516677819","title":"戴纳基盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677819","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677819?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:33","pubTimestamp":1741098836,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时33分，戴纳基股票出现异动，股价急速下跌5.03%。截至发稿，该股报11.70美元/股，成交量2.8713万股，换手率0.03%，振幅3.53%。机构评级方面，在所有12家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体跌幅为0.01%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503042233569639453a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503042233569639453a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4588","BK4585","BK4139","DYN"],"gpt_icon":0},{"id":"2514332688","title":"戴纳基盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514332688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514332688?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:14","pubTimestamp":1740687278,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时14分，戴纳基股票出现异动，股价大幅跳水5.15%。截至发稿，该股报13.08美元/股，成交量119.587万股，换手率1.18%，振幅7.83%。机构评级方面，在所有11家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体跌幅为0.32%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228041438a256c675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228041438a256c675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","DYN","BK4588","BK4585"],"gpt_icon":0},{"id":"1167334766","title":"Dyne Therapeutics 2024年第四季度每股收益 $(0.88)，优于预期$(0.99)","url":"https://stock-news.laohu8.com/highlight/detail?id=1167334766","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167334766?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:44","pubTimestamp":1740660293,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  报告称季度每股亏损为$，比分析师一致预期的$高出11.11%。与去年同期每股亏损$相比，这是一个19.27%的改善。以上内容来自Benzinga Earnings专栏，原文如下：Dyne $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 11.11 percent. This is a 19.27 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DYN"],"gpt_icon":0},{"id":"2510338174","title":"戴纳基盘中异动 股价大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510338174?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:59","pubTimestamp":1739285988,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时59分，戴纳基股票出现波动，股价大幅跳水5.32%。截至发稿，该股报13.71美元/股，成交量7.4737万股，换手率0.07%，振幅3.59%。戴纳基股票所在的生物技术行业中，整体跌幅为1.29%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112259489881c28a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112259489881c28a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4505","BK4585","DYN"],"gpt_icon":0},{"id":"2510898560","title":"戴纳基盘中异动 大幅下跌5.07%报14.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510898560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510898560?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:15","pubTimestamp":1739207744,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时15分，戴纳基股票出现波动，股价大幅下挫5.07%。截至发稿，该股报14.59美元/股，成交量21.8308万股，换手率0.21%，振幅5.47%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-97.13百万美元，每股收益-0.96美元，毛利-400000.00美元，市盈率-4.10倍。戴纳基股票所在的生物技术行业中，整体跌幅为0.22%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011544961e1fd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011544961e1fd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","DYN","BK4585","BK4505","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dyne-tx.com","stockEarnings":[{"period":"1week","weight":-0.0201},{"period":"1month","weight":0.1417},{"period":"3month","weight":-0.1154},{"period":"6month","weight":0.3374},{"period":"1year","weight":0.4323},{"period":"ytd","weight":-0.1022}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dyne Therapeutics, Inc.于2017年12月1日根据特拉华州法律注册成立。该公司正在建立一家领先的肌肉疾病公司，致力于开发针对遗传驱动疾病患者的创新性改变生命的疗法。该公司正在利用其专有的FORCE平台来克服当前肌肉组织输送的局限性，并发展用于肌肉疾病的现代寡核苷酸疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.011425},{"month":2,"riseRate":0.333333,"avgChangeRate":0.013319},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031962},{"month":4,"riseRate":0.4,"avgChangeRate":0.002599},{"month":5,"riseRate":0.6,"avgChangeRate":0.021103},{"month":6,"riseRate":0.6,"avgChangeRate":0.059122},{"month":7,"riseRate":0.8,"avgChangeRate":0.143805},{"month":8,"riseRate":0.4,"avgChangeRate":0.05015},{"month":9,"riseRate":0.2,"avgChangeRate":-0.048359},{"month":10,"riseRate":0.333333,"avgChangeRate":0.031774},{"month":11,"riseRate":0.5,"avgChangeRate":0.097108},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.044634}],"exchange":"NASDAQ","name":"戴纳基","nameEN":"Dyne Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"戴纳基(DYN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供戴纳基(DYN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"戴纳基,DYN,戴纳基股票,戴纳基股票老虎,戴纳基股票老虎国际,戴纳基行情,戴纳基股票行情,戴纳基股价,戴纳基股市,戴纳基股票价格,戴纳基股票交易,戴纳基股票购买,戴纳基股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"戴纳基(DYN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供戴纳基(DYN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}